Electromed (ELMD)
XASE:ELMD
Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$24.83
$0.65(2.15%)
At close: 4:00 PM EST
$24.83
$0.65(2.15%)
Day’s Range― - ―
52-Week Range$17.73 - $40.00
Previous CloseN/A
Volume34.94K
Average Volume (3M)62.07K
Market Cap
$302.88M
Enterprise Value$295.34M
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)29.7
Beta0.73
Next Earnings
Sep 01, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding8,280,064
10 Day Avg. Volume73,592
30 Day Avg. Volume62,066
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.24
Price to Sales (P/S)2.86
P/FCF Ratio16.53
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.12
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda20.36
Forecast
1Y Price Target
$38.00Price Target Upside53.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.17
Revenue Forecast (FY)$73.33M
Bulls Say, Bears Say
Bulls Say
High And Durable MarginsSustained gross margins near 78% and rising net margins provide durable operating profitability that supports reinvestment in sales and product support. High margin mix (device plus supplies) cushions profitability versus volume swings and enables margin-led scalability over months.
Debt-free, Liquid Balance SheetA zero-debt, cash-positive balance sheet with sizable working capital delivers financial flexibility to fund commercialization, absorb reimbursement timing, and pursue repurchases or targeted investments without leverage. This conservatism reduces financing risk over the medium term.
Operational & Commercial ExecutionAdoption of ePrescribe and completed manufacturing improvements shorten fulfillment cycles and lower operating friction, improving conversion economics and capacity to scale. These structural ops upgrades support sustainable revenue growth and margin resilience over several quarters.
Bears Say
Reliance On Salesforce RampManagement links incremental growth to expanding and ramping field reps; new reps take 4–6 months to reach productivity. This creates persistent execution risk: hiring delays, variable onboarding outcomes, or increased labor costs can slow revenue conversion for multiple quarters.
Historical Cash-flow VolatilityWhile TTM cash aligns with earnings, prior years showed negative operating and free cash flow, indicating working-capital swings and investment timing can materially affect cash conversion. Recurrence could constrain reinvestment or capital returns across multiple quarters.
Payer/guideline & Conversion UncertaintyLong-term market penetration hinges on payer policies, formal clinical guidelines, and clinician prescribing behavior. Unpublished guidance and unclear conversion from outreach mean adoption gains could be uneven and dependent on external regulatory and reimbursement developments over many months.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $17.73 and its highest was $40.00 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $302.88M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Sep 01, 2026 which is in 90 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on May 12, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.1.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.32.
How many shares outstanding does Electromed have?
Electromed has 8,280,064 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.35 in its last earnings report, beating expectations of $0.25. Following the earnings report the stock price went up 25.11%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (53.04% Upside)
$38.00 (53.04% Upside)
Blogger Sentiment
Bullish
ELMD Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 35.7%
Last 30 Days ▲ 35.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.78%
12-Months-Change
Fundamentals
Return on Equity
22.14%
Trailing 12-Months
Asset Growth
13.39%
Trailing 12-Months
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Company Deck
ELMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong, broad-based financial performance (double-digit revenue growth, high operating leverage, margin durability), improved operational capability (completed manufacturing optimization, ePrescribe adoption), a healthy balance sheet (cash, no debt) and a large addressable bronchiectasis market supported by active clinical and digital outreach. Challenges include modest non-core revenue, reliance on ramping sales rep headcount for incremental growth, slowed share repurchases due to macro uncertainty, and remaining uncertainty on guideline publication and conversion rates from clinician engagement. Overall, the positives (robust revenue and profit expansion, operational wins, market opportunity) substantially outweigh the negatives.View all ELMD earnings summariesELMD Stock 12 Month Forecast
Average Price Target
$38.00
▲(53.04% Upside)
Technical Analysis
Ownership Overview
7.21% Insiders
10.39% Mutual Funds
16.67% Other Institutional Investors
56.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---